PHILADELPHIA--(BUSINESS WIRE)-- Lannett Company, Inc. (AMEX: LCI), a manufacturer of generic pharmaceuticals, announced today that it has received approval from the U.S. Food and Drug Administration ...
Another randomized multicenter study was conducted by Seynaeve and collegues [4] and included 535 chemotherapy- naive patients receiving cisplatin, 50-120 mg/m 2. Patients were randomized to receive ...
Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. This was a multicenter, randomized, double-blind, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results